Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Nimotuzumab + Vinorelbine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Nimotuzumab | Theraloc|hR3 | EGFR Antibody 73 | Nimotuzumab is a humanized anti-EGFR antibody that blocks EGFR signaling, resulting in anti-tumor activity (PMID: 25842083, PMID: 32588692, PMID: 32021306). | |
| Vinorelbine | Navelbine | Vinorelbin | Antimicrotubule Agent 14 | Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03620032 | Phase II | Nimotuzumab + Vinorelbine | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses (DIPG) | Unknown status | ITA | 0 |